{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:17:25Z","timestamp":1790201845196,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T00:00:00Z","timestamp":1250208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p><jats:bold>Objective\u2002<\/jats:bold> To determine maternal and fetal outcomes in women with mechanical heart valves managed with therapeutic dose enoxaparin during pregnancy.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Retrospective audit.<\/jats:p><jats:p><jats:bold>Setting\u2002<\/jats:bold> Hospital\u2010based high\u2010risk antenatal clinics.<\/jats:p><jats:p><jats:bold>Population\u2002<\/jats:bold> Pregnant women with mechanical heart valves attending high\u2010risk antenatal clinics, treated with enoxaparin (1\u2003mg\/kg twice daily) during pregnancy.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Women with mechanical heart valves treated with enoxaparin at any stage during pregnancy (1997\u20132008) identified using a database of women with mechanical heart valves attending the high\u2010risk clinics and a prospective database of women prescribed enoxaparin for any indication during pregnancy.<\/jats:p><jats:p><jats:bold>Main outcome measures\u2002<\/jats:bold> Maternal outcomes included thromboembolic and haemorrhagic complications. Pregnancy and fetal outcomes included miscarriage, stillbirth, baby death and live birth, small\u2010for\u2010gestational\u2010age infants, warfarin embryopathy and warfarin\u2010related fetal loss.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Thirty\u2010one women underwent 47 pregnancies. In 34 pregnancies (72.3%), anticoagulation was with predominantly enoxaparin and 13 (27.7%) pregnancies women received mainly warfarin, with enoxaparin given in the first trimester and\/or peri\u2010delivery. Seven (14.9%) thrombotic complications occurred, of which five (10.6%) were associated with enoxaparin treatment. Non\u2010compliance or sub\u2010therapeutic anti\u2010Xa levels contributed in each case. Antenatal and postpartum haemorrhagic complications occurred in eight (17%) and 15 (32%) pregnancies respectively. Of 35 pregnancies continuing after 20\u2003weeks\u2019 gestation, 96% (22\/23) of women taking predominantly enoxaparin had a surviving infant compared with 75% (9\/12) in women taking primarily warfarin. Four perinatal deaths occurred, three attributable to warfarin.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Compliance with therapeutic dose enoxaparin and aspirin during pregnancy in women with mechanical heart valves is associated with a low risk of valve thrombosis and good fetal outcomes, but close monitoring is essential.<\/jats:p>","DOI":"10.1111\/j.1471-0528.2009.02299.x","type":"journal-article","created":{"date-parts":[[2009,8,14]],"date-time":"2009-08-14T09:36:39Z","timestamp":1250242599000},"page":"1585-1592","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":139,"title":["Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin"],"prefix":"10.1111","volume":"116","author":[{"given":"C","family":"McLintock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LME","family":"McCowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RA","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,9]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.007"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0761"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.2.191"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-06-0337"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/14767050600886666"},{"key":"e_1_2_11_7_2","unstructured":"HIP\u2010CAT study.Data on file. Aventis Pharmaceuticals."},{"key":"e_1_2_11_8_2","first-page":"101","article-title":"Is there a safe anticoagulation protocol for pregnant women with prosthetic valves?","volume":"25","author":"Arnaout MS","year":"1998","journal-title":"Clin Exp Obstet Gynecol"},{"key":"e_1_2_11_9_2","first-page":"127","article-title":"Anti\u2010Xa activity with low\u2010molecular\u2010weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves","volume":"45","author":"Izaguirre R","year":"2002","journal-title":"Proc West Pharmacol Soc"},{"key":"e_1_2_11_10_2","first-page":"97b","article-title":"Low molecular weight heparin (LMWH) for thromboprophylaxis during pregnanciy in patients with mechanical heart valves","volume":"96","author":"Lee LH","year":"2000","journal-title":"Blood"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003920170020"},{"issue":"1","key":"e_1_2_11_12_2","first-page":"P1479","article-title":"Low molecular weight heparin (LMWH) in pregnant women with mechanical prosthetic heart valves","volume":"1","author":"Meschengieser SS","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.117657"},{"key":"e_1_2_11_14_2","first-page":"370","article-title":"Pregnancy after mechanical mitral valve replacement","volume":"12","author":"Vural KM","year":"2003","journal-title":"J Heart Valve Dis"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2005.00656.x"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/tera.10054"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.02.087"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.12.005"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308193290802"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040040-00003"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016349609047090"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(01)01658-1"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-0528.2009.02299.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-0528.2009.02299.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:46:41Z","timestamp":1697410001000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-0528.2009.02299.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,9]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1471-0528.2009.02299.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-0528.2009.02299.x","archive":["Portico"],"relation":{},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,9]]},"assertion":[{"value":"2009-10-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}